Methods for inhibiting HIV-1 infection
AssigneeProgenics Pharmaceuticals, Inc.
InventorsVirginia M. Litwin, Graham P. Allaway, Paul J. Maddon
Life of this patent
Estimating the term…
Abstract
This invention provides an antibody capable of specifically inhibiting the fusion of an HIV-1 envelope glycoprotein+ cell with an appropriate CD4+ cell without cross reacting with the HIV-1 envelope glycoprotein or CD4 and capable of inhibiting infection by one or more strains of HIV-1. This antibody is then used to identify a molecule which is important for HIV infection. Different uses of the antibody and the molecule are described.
Claims8
A method of inhibiting HIV-1 infection of a CD4+ cell which comprises contacting the CD4+ cell with an amount of a monoclonal antibody or portion thereof effective to (a) specifically inhibit 67% or greater of fusion of a CD4+ PM-1 cell to a HeLa cell expressing envelope glycoprotein from HIV-1JR-FL, and (b) inhibit 18% or less of fusion of a CD4+ SUP-T1 cell to a HeLa cell expressing envelope protein from HIV-1LAI, wherein the antibody (i) does not crossreact with HIV-1 envelope glycoprotein or CD4, (ii) reacts with an antigen on the surface of a PM-1 cell having an approximate molecular weight of 44 kD, (iii) does not react with an antigen on the surface of a SUP-T1 cell, and (iv) is at least as active as monoclonal antibody PA-7 produced by the hybridoma designated PA-7 (ATCC Accession No. PTA-6638) in inhibiting fusion as recited in (a) above and less active than monoclonal antibody PA-6 produced by the hybridoma designated PA-6 (ATCC Accession No. PTA-6637) in inhibiting fusion as recited in (b) above, so as to thereby inhibit HIV-1 infection of the CD4+ cell.
Dependencies are inferred from the claim text.